评估前列腺癌[68Ga]Ga-PSMA-11 PET/CT中局灶性骨病变形态学改变的发生频率与准确性
单中心回顾性研究纳入323例前列腺癌患者,分析[68Ga]Ga-PSMA-11 PET/CT上局灶性骨摄取伴或不伴CT形态学改变的发生频率与恶性比例。初诊分期组无形态学改变者占25%(其中73%为恶性),生化复发组无形态学改变者占52%(其中48%为恶性)。PSMA-RADS 2.0联合CT形态学在初诊分期组灵敏度/特异度达100%/100%,生化复发组为83%/100%。
要点
- 初诊分期组61个病灶中25%无CT形态学改变,其中73%为恶性。
- 生化复发组115个病灶中52%无CT形态学改变,其中48%为恶性。
- PSMA-RADS 2.0联合CT形态学在初诊分期组灵敏度/特异度100%/100%。
核心结论
- 局灶性[68Ga]Ga-PSMA-11阳性骨病变无CT形态学改变者常见,尤其在生化复发扫描中,且多数为恶性。
- 初诊分期检查中考虑PSMA-RADS 4病变可显著提高准确性。
- 纳入临床信息并考虑PSMA-RADS 3B可进一步提高生化复发扫描的灵敏度。
研究设计与样本
- 824例患者中323例符合标准,101例显示PSMA阳性骨病变,共纳入176个病灶。
- 每个患者最多3个骨内局灶性PSMA摄取病灶按PSMA-RADS 2.0评分并给出结合临床信息的恶性怀疑临床解读,同时评估CT形态学改变。
- 采用包括影像和临床随访数据的复合参考标准。
主要发现
- 初诊分期组61个病灶中25%无CT形态学改变,其中73%为恶性。
- 生化复发组115个病灶中52%无CT形态学改变,其中48%为恶性。
- PSMA-RADS 2.0的灵敏度/特异度在初诊分期组为100%/100%,在生化复发组为83%/100%。
- CT形态学改变的灵敏度/特异度在初诊分期组为78%/36%,在生化复发组为60%/72%。
关键数值与推荐
- PSMA-RADS 2.0评分系统。
- CT形态学改变评估。
- 复合参考标准包括影像和临床随访数据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In [18F]F-PSMA-1007 PET imaging, focal bone uptake without morphological correlate (MC) on CT, is often classified as benign. In [68Ga]Ga-PSMA-11, intense focal uptake without MC in a classical location is considered suspicious. The prevalence of focal bone uptake with or without MC on [68Ga]Ga-PSMA-11 PET/CT remains unclear. METHODS: This single-center, retrospective study included patients who underwent a [68Ga]Ga-PSMA-11 PET/CT scan for initial staging or biochemical recurrence (BCR) of prostate cancer between 04/16 - 11/21, with written informed consent for use of clinical data and adequate follow-up. For each patient with focal PSMA accumulation in the bones, up to three of these lesions were scored based on PSMA-RADS 2.0 and a clinical interpretation of suspicion for malignancy including clinical information was provided. In addition, MC on CT were assessed. A composite reference standard including imaging and clinical follow-up data was used. RESULTS: Out of 824 patients, 323 met eligibility criteria, with 101 showing PSMA-positive bone lesions. 176 lesions were included, 25% of 61 in the staging cohort had no MC, of which 73% were malignant. In the BCR group, 52% of 115 lesions were without MC, of which 48% were malignant. The sensitivity/specificity reached with PSMA-RADS 2.0, and MC on CT was 100%/100%and 78%/36% for staging, and 83%/100% and 60%/72% for BCR, respectively. CONCLUSION: Focal [68Ga]Ga-PSMA-11 positive lesions without MC on CT are frequent, especially on scans for BCR, with the majority being malignant. Considering PSMA-RADS 4 lesions on [68Ga]Ga-PSMA-11 on staging exams, significantly improves the accuracy. Incorporating clinical information and considering PSMA-RADS 3B can further improve the sensitivity for BCR scans.
引用
- Sivakumar T, Heimer J, Beintner-Skawran S, et al. Assessing the frequency and accuracy of morphologic changes of focal bone lesions on [68Ga]Ga-PSMA-11 PET/CT in prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40523941. doi:10.1007/s00259-025-07331-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。